Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2022 · 10-Q
Revenue—
Net Income-$8.94M-$8.94MN/M vs Q1 2021 EPS Diluted-$2.40-$2.40N/M vs Q1 2021 Operating Cash Flow-$9,347,000N/M Free Cash Flowderived-$10,470,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end